Cellular Biomedicine Group
530 University Avenue
136 articles about Cellular Biomedicine Group
There are more than 900 regenerative medicine trials underway globally, including trials in cell and gene therapy, a 19 percent increase since 2016
Cellular Biomedicine added $14.5M into its treasury through two private placements, one to key executives and the other to outside investors.
The Company intends to use the proceeds from the financings to fund clinical trials and more.
Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Operational Highlights
$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017.
The company held a Grand Opening ceremony on November 4, 2017 for its new Shanghai facility located in “Pharma Valley” in Shanghai Zhangjiang High-Tech Park.
Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
The partnership focuses on the research and development of an automated cell therapy manufacturing system.
BioLife Solutions, Inc. CryoStor Cell Freeze Media Embedded In Cellular Biomedicine Group Clinical Trial Of AlloJoin
Cellular Biomedicine Group Reports Second Quarter And First Half 2017 Financial Results And Business Highlights
Cellular Biomedicine Group Appoints Dr. Xia Meng As Chief Operating Officer To Lead Commercialization Of The Company’s CAR-T And Stem Cell Products
Cellular Biomedicine Group (CBMG) Announces Publication Titled "Target Cell Killing Effects Of CD20 Targeting Chimeric Antigen Receptor T Cells Derived From The Type Ii Anti-CD20 Antibody" In Conjunction With 2017 ASCO Annual Meeting
Cellular Biomedicine Group And GE Healthcare Life Sciences China Announce Strategic Partnership To Establish Joint Technology Laboratory To Develop Control Processes For The Manufacture Of CAR-T And Stem Cell Therapies
Cellular Biomedicine Group Awarded $2.29 Million Grant From The California Institute For Regenerative Medicine (CIRM) To Fund AlloJoin Allogeneic Stem Cell Therapy For Knee Osteoarthritis (KOA) In The U.S.
Cellular Biomedicine Group To Present At The Piper Jaffray 27th Annual Healthcare Investor Conference
Cellular Biomedicine Group Presented Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma